Whether the body tolerates a material vs. whether the material tolerates the body over time — two independent questions, not two names for one.
It's a natural assumption that a material safe enough to put in the body must also be a material built to last in the body — but nothing about being non-toxic implies durability. Biocompatibility asks a biological question: does the material provoke an adverse local or systemic response — inflammation, toxicity, an immune reaction — when it contacts tissue or blood? Biostability asks an entirely different, materials-science question: does the material resist chemical and mechanical degradation, corrosion, or dissolution over its intended service life in the body's aggressive physiological environment? A material can be biocompatible and biostable (titanium in a hip stem), biocompatible and deliberately not biostable (a resorbable suture), or — critically — biostable but not biocompatible (a durable material that nonetheless provokes a chronic adverse response).
Biocompatibility is evaluated through the ISO 10993 series — cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, and other endpoints selected based on the device's nature and duration of body contact. These tests answer a snapshot-in-time biological question: does exposure to this material, in this form, provoke a measurable adverse response. Biostability is evaluated through accelerated aging studies, corrosion testing (for metals), hydrolytic and oxidative degradation testing (for polymers), and long-term implant retrieval and mechanical property data — these tests answer a time-dependent materials-science question: what does this material's structure and mechanical performance look like after months or years of exposure to physiological saline, enzymes, mechanical loading, and the body's own foreign-body response. Neither test battery substitutes for the other, because they're measuring genuinely different failure modes.
The engineering task isn't to maximize both properties — it's to select the right combination for the device's intended function and duration of body contact. A permanent structural implant like a hip stem or a pacemaker can needs both biocompatibility and long-term biostability, because premature degradation of a load-bearing or hermetically sealed component is itself a safety failure. A resorbable suture or a bioresorbable drug-eluting stent scaffold is deliberately engineered to be biocompatible while being explicitly non-biostable — its function requires it to degrade into biocompatible byproducts on a controlled timeline and disappear once its temporary mechanical or scaffolding job is done. Specifying a resorbable device's material as though it needed permanent biostability would be a design error in the opposite direction — over-engineering durability into a device meant to vanish.
A polymer like polyglycolic acid is engineered to hydrolyze in the body over a predictable timeframe, breaking down into glycolic acid and ultimately into water and carbon dioxide through normal metabolic pathways. The material's lack of biostability isn't a limitation being tolerated — it's the design feature. But that only works because the degradation byproducts are themselves biocompatible; a material that degraded into toxic or inflammatory byproducts would fail biocompatibility testing even though it might satisfy the intended non-biostable service profile. Biocompatibility has to hold not just for the intact material but across its entire degradation pathway.
Standard ISO 10993 biocompatibility testing evaluates the material largely as manufactured, over the endpoints appropriate to the intended contact duration — it does not, by itself, establish how that material's mechanical properties or chemical composition change after years of physiological exposure. A material can pass initial biocompatibility screening and still corrode, crack, leach degradation products, or lose mechanical integrity over years in the body if its biostability was never separately characterized for that service life. Long-term implants require both biocompatibility data and biostability data — one doesn't imply the other.
Explains why biocompatibility (whether a material provokes an adverse biological response) and biostability (whether a material resists chemical and mechanical degradation over its service life) are independent material properties, evaluated by different test methods, and why device intent — not a blanket preference for durability — determines which combination of the two a given material needs. Covers why a resorbable suture is deliberately biocompatible without being biostable.
Because both terms describe a material's relationship with the body, it's easy to treat them as roughly synonymous — a 'good' biomedical material sounds like it should be safe and durable. But they answer different questions on different timescales: biocompatibility is a snapshot question about biological response, evaluated largely through short-to-medium duration testing per ISO 10993. Biostability is a longitudinal question about material integrity, evaluated through accelerated aging and long-term degradation testing. A material can score well on one and poorly on the other, and for certain devices — resorbable ones — scoring poorly on biostability is the entire point.
Biocompatibility evaluation follows the ISO 10993 series, with the specific test battery (cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation, hemocompatibility, and others) selected based on the device's nature of body contact (surface, external communicating, or implant) and contact duration (limited, prolonged, or permanent) per ISO 10993-1's device categorization matrix. Biostability evaluation has no single unifying standard in the same way; it draws on material-specific approaches — ASTM corrosion testing for metals, hydrolytic and oxidative degradation protocols for polymers, and accelerated aging per ASTM F1980 or similar for predicting real-time shelf and service-life behavior — combined with mechanical property testing before and after simulated aging.
Material selection for any implantable or long-duration-contact device should explicitly separate these two evaluations rather than treating a single biocompatibility data package as sufficient justification. Permanent implants need both properties characterized for the device's full intended service life — often 10+ years for orthopedic and cardiovascular implants. Resorbable and biodegradable devices need biocompatibility confirmed not just for the parent material but across its full degradation product profile, since the byproducts the body is exposed to change over the device's functional life. Skipping either evaluation, or assuming one implies the other, is a common root cause of late-stage design changes when unanticipated degradation or biological response surfaces in long-term testing.
Yes. Polymer chemistry, molecular weight, crystallinity, and cross-linking density can all be tuned to shift a material's degradation rate dramatically while keeping its general biocompatibility profile similar. Different grades and formulations of related polymer families are deliberately engineered across a spectrum from essentially permanent to rapidly resorbable, which is exactly why material selection specifies not just a chemical family but a specific grade, molecular weight, and processing history matched to the device's intended degradation timeline.
Generally yes in practice, because changing molecular weight, crystallinity, or formulation to alter degradation kinetics typically also changes the degradation byproduct profile and release kinetics the body is exposed to over time — both of which are biocompatibility-relevant. Regulatory guidance and ISO 10993-1's risk-based framework call for evaluating whether a material change is significant enough to warrant re-testing, and a deliberate biostability change is usually significant enough to trigger at least a documented risk assessment, if not new testing.
Corrosion resistance is one specific mechanism under the broader biostability umbrella for metallic materials — it describes resistance to electrochemical degradation in the body's saline, oxygen-containing physiological environment. Biostability is the broader property (does the material resist degradation of any kind — chemical, mechanical, or otherwise — over its service life), and for metals, corrosion resistance is usually the dominant, though not the only, biostability concern; fatigue and wear resistance under cyclic physiological loading matter too.
Try our Biomedical Engineering
More calculators, simulators, and guides for this discipline.